Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis

医学 肺癌 内科学 荟萃分析 肿瘤科 科克伦图书馆 危险系数 不利影响 安慰剂 随机对照试验 相对风险 梅德林 置信区间 替代医学 病理 法学 政治学
作者
Yan Lu,Chenbing Sun,Lijing Jiao,Yu Liu,Yabin Gong,Ling Xu
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:12 被引量:3
标识
DOI:10.3389/fphar.2021.698371
摘要

Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. First-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly improve prognosis of advanced NSCLC patients harboring EGFR sensitizing mutation. However, acquired resistance to EGFR-TKIs limits the good outcomes. Chinese herbal medicine (CHM) has been used for NSCLC patients receiving EGFR-TKIs for more than 10°years as an adjuvant treatment. Methods: Studies were searched from China BioMedical Literature, Chinese National Knowledge Infrastructure, Cqvip Database, Wanfang Database, MEDLINE (PubMed), EMBASE (Ovid), Google Scholar, and Cochrane Library from inception to March, 2021. Randomized controlled clinical trials (RCT) comparing EGFR-TKIs + CHM (TKIs + CHM) versus EGFR-TKIs with/without placebo (TKIs ± placebo) in participants with advanced NSCLC harboring EGFR sensitizing mutation were included in this study. Two authors screened all references, assessed the risk of bias and extracted data independently. Data were summarized using hazard ratio (HR) and risk ratios (RR), with 95% confidence intervals (CI) for binary outcomes. Meta-analysis was performed using random effects model. Overall quality of evidence was assessed using GRADE. Results: A total of 9 RCTs (1137 participants, 581 in the TKIs + CHM group and 556 in the TKIs ± placebo group) were included in this review. Only first-generation EGFR-TKIs were included. Most trials included used oral CHM preparations to tonify Qi and/or Yin. Treatment lasted from enrollment until disease progression (PD) or intolerable adverse events (AE). Combination of CHM with EGFR-TKIs improved median progression-free survival (mPFS) (HR,0.59; 95% CI, 0.52–0.68; P < 0.00001) and objective response rate (ORR) (RR, 1.23; 95% CI, 1.13–1.34; P < 0.00001) compared with used of EGFR-TKIs ± placebo. CHM reduced AE associated with EGFR-TKIs such as cutaneous toxicity (RR, 0.58; 95% CI, 0.46–0.73; P < 0.00001) and diarrhea (RR, 0.43; 95% CI, 0.30–0.60; P < 0.00001). Conclusion: Combination therapy of CHM and EGFR-TKIs significantly delays acquired resistance while improving ORR to EGFR-TKIs. Furthermore, CHM reduces AE induced by EGFR-TKIs. More international multi-centered, double-blinded, placebo-controlled, well-designed clinical trials are needed in future research.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
云中雾完成签到,获得积分10
刚刚
华清如发布了新的文献求助10
刚刚
刚刚
liangchao发布了新的文献求助10
1秒前
Elaine完成签到,获得积分10
1秒前
rudjs完成签到,获得积分10
1秒前
ding的应助被qianlan采纳,获得10
1秒前
醉熏的西牛完成签到 ,获得积分10
1秒前
被风吹过的路的应助被gjy采纳,获得10
2秒前
蔚岚影落完成签到,获得积分10
2秒前
傻芙芙的完成签到,获得积分10
2秒前
2秒前
HXX完成签到,获得积分10
2秒前
ohh完成签到,获得积分10
3秒前
Ethanyoyo0917完成签到,获得积分10
3秒前
云焕完成签到,获得积分10
3秒前
简单若风完成签到,获得积分10
3秒前
3秒前
轻松忆翠完成签到,获得积分10
3秒前
烤鸭本鸭完成签到,获得积分10
3秒前
小洛完成签到,获得积分10
3秒前
天天向上完成签到,获得积分10
3秒前
翟翟翟完成签到,获得积分10
3秒前
4秒前
DY完成签到,获得积分10
4秒前
HuBasya发布了新的文献求助10
4秒前
自信雪冥完成签到,获得积分10
4秒前
KingYugene完成签到,获得积分0
4秒前
4秒前
jie发布了新的文献求助10
4秒前
Szn完成签到,获得积分10
5秒前
淡然的奎完成签到,获得积分0
5秒前
独特秋双完成签到,获得积分10
5秒前
吨吨喝水发布了新的文献求助10
5秒前
5秒前
ssw完成签到,获得积分10
5秒前
Sylvia完成签到 ,获得积分10
5秒前
nulinuli完成签到 ,获得积分10
5秒前
swallow完成签到,获得积分10
5秒前
庸俗完成签到 ,获得积分10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042